PL2252301T3 - Zastosowanie uliprystalu do leczenia mięśniaków macicy - Google Patents

Zastosowanie uliprystalu do leczenia mięśniaków macicy

Info

Publication number
PL2252301T3
PL2252301T3 PL09706347T PL09706347T PL2252301T3 PL 2252301 T3 PL2252301 T3 PL 2252301T3 PL 09706347 T PL09706347 T PL 09706347T PL 09706347 T PL09706347 T PL 09706347T PL 2252301 T3 PL2252301 T3 PL 2252301T3
Authority
PL
Poland
Prior art keywords
ulipristal
uterine fibroids
treating uterine
treating
fibroids
Prior art date
Application number
PL09706347T
Other languages
English (en)
Inventor
Erin Gainer
Lynnette Nieman
André Ulmann
Diana Blithe
Original Assignee
Us Health
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2252301(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health, Hra Pharma Lab filed Critical Us Health
Publication of PL2252301T3 publication Critical patent/PL2252301T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PL09706347T 2008-01-29 2009-01-28 Zastosowanie uliprystalu do leczenia mięśniaków macicy PL2252301T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
EP09706347.3A EP2252301B1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (1)

Publication Number Publication Date
PL2252301T3 true PL2252301T3 (pl) 2014-07-31

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09706347T PL2252301T3 (pl) 2008-01-29 2009-01-28 Zastosowanie uliprystalu do leczenia mięśniaków macicy

Country Status (20)

Country Link
US (5) US8299050B2 (pl)
EP (2) EP2252301B1 (pl)
JP (2) JP5906016B2 (pl)
KR (2) KR101571400B1 (pl)
AU (1) AU2009209652B2 (pl)
BR (1) BRPI0907028B8 (pl)
CA (2) CA2713254C (pl)
CY (1) CY1116485T1 (pl)
DK (1) DK2252301T3 (pl)
ES (1) ES2450592T3 (pl)
HR (1) HRP20140132T1 (pl)
IL (2) IL207182A (pl)
MX (1) MX2010008270A (pl)
NZ (1) NZ587439A (pl)
PL (1) PL2252301T3 (pl)
PT (1) PT2252301E (pl)
SI (1) SI2252301T1 (pl)
TW (1) TWI445537B (pl)
WO (1) WO2009095418A1 (pl)
ZA (1) ZA201006049B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
KR102166867B1 (ko) * 2010-03-22 2020-10-19 앨러간 파마슈티컬스 인터내셔널 리미티드 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US20150320766A1 (en) * 2012-12-14 2015-11-12 Laboratoire Hra-Pharma Copper intrauterine device
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
NZ712984A (en) * 2013-04-10 2020-07-31 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
EP3223843B1 (en) * 2014-11-24 2019-06-19 Ramot at Tel-Aviv University Ltd. Pigment epithelium derived factor (pedf) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
EP4106530A1 (en) 2020-02-19 2022-12-28 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
JPH10512889A (ja) 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6861415B2 (en) 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
KR20010032056A (ko) 1997-11-14 2001-04-16 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 황체 호르몬-항 황체 호르몬 투약법
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
CA2623678A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
JP2010514793A (ja) * 2006-12-28 2010-05-06 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンのバイオアベイラビリティを改善するための方法および製剤
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
US20090192130A1 (en) 2009-07-30
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
JP6138838B2 (ja) 2017-05-31
CA2713254A1 (en) 2009-09-06
IL207182A0 (en) 2010-12-30
US9180133B2 (en) 2015-11-10
JP2015120711A (ja) 2015-07-02
BRPI0907028A8 (pt) 2019-08-13
EP2252301B1 (en) 2013-12-11
AU2009209652A1 (en) 2009-08-06
EP2252301A1 (en) 2010-11-24
EP2684565A1 (en) 2014-01-15
BRPI0907028B8 (pt) 2021-05-25
IL207182A (en) 2015-06-30
US8299050B2 (en) 2012-10-30
IL234149B (en) 2019-02-28
TW200944211A (en) 2009-11-01
ZA201006049B (en) 2011-05-25
US20170246189A1 (en) 2017-08-31
WO2009095418A1 (en) 2009-08-06
ES2450592T3 (es) 2014-03-25
CA2713254C (en) 2014-10-07
MX2010008270A (es) 2011-01-14
JP2011510949A (ja) 2011-04-07
NZ587439A (en) 2012-06-29
IL234149A0 (en) 2014-09-30
BRPI0907028A2 (pt) 2015-07-07
HRP20140132T1 (hr) 2014-05-09
BRPI0907028B1 (pt) 2019-09-24
US9682088B2 (en) 2017-06-20
US8722653B2 (en) 2014-05-13
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
US20140187525A1 (en) 2014-07-03
DK2252301T3 (en) 2014-02-17
US20130023506A1 (en) 2013-01-24
AU2009209652B2 (en) 2013-03-21
CY1116485T1 (el) 2017-03-15
CA2857798A1 (en) 2009-09-06
EP2684565B1 (en) 2019-10-02
TWI445537B (zh) 2014-07-21
KR101571400B1 (ko) 2015-11-24
JP5906016B2 (ja) 2016-04-20
KR20110021709A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
ZA201006049B (en) Use of ulipristal for treating uterine fibroids
HK1162916A1 (en) Methods of treatment for solid tumors
EP2521724A4 (en) ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES
EP2552546A4 (en) OFFICE COMPATIBLE SYSTEM FOR THE TREATMENT OF NUTRITIONAL FIBROMES OR OTHER WOVEN FABRICS WITH HIFU
GB0803514D0 (en) Customised surgical apparatus
EP2252148A4 (en) METHOD FOR THE TREATMENT OF DARM DISEASES
HK1159008A1 (en) Apparatus for treating tissues with hifu hifu
IL208354A0 (en) Methods of treatment
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
PL2473592T3 (pl) Zastosowanie środków do traktowania twardych powierzchni
EP2327974A4 (en) TISSUE TREATMENT DEVICE
ZA201204845B (en) Agents for treating disease
EP2501371A4 (en) USE OF HYDROXYTYROSOL FOR IMPROVED MUSCLE DIFFERENTIATION
EP2308405A4 (en) HIGH FREQUENCY TREATMENT INSTRUMENT
EP2327367A4 (en) INSTRUMENT FOR ENDOSCOPIC TREATMENT
EP2411020A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGE
EP2331113A4 (en) COMPLEMENTARY INHIBITORS FOR THE TREATMENT OF INTRACEREBRAL HEMORRHAGE DAMAGE
PL2249735T3 (pl) Przyrząd elektrochirurgiczny
IL213287A0 (en) Treatment for glomerulonephritis
SI2244572T1 (sl) Uporaba kongenerjev ibogamina za zdravljenje debelosti
GB0920940D0 (en) Agent for treating disease
GB0920942D0 (en) Agent for treating disease
GB0920933D0 (en) Agent for treating disease